The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Early tumor shrinkage as a predictor of favorable outcomes in patients (pts) with advanced pancreatic cancer treated with FOLFIRINOX.
 
Yasuhiro Kaga
No Relationships to Disclose
 
Yu Sunakawa
Honoraria - Chugai Pharma; Daiichi Sankyo; Merck Serono; Taiho Pharmaceutical; Takeda
 
Yutaro Kubota
No Relationships to Disclose
 
Teppei Tagawa
No Relationships to Disclose
 
Taikan Yamamoto
No Relationships to Disclose
 
Toshikazu Ikusue
No Relationships to Disclose
 
Yu Uto
No Relationships to Disclose
 
Yu Kitahara
No Relationships to Disclose
 
Hirokazu Toshima
No Relationships to Disclose
 
Kouji Kobayashi
No Relationships to Disclose
 
Atsushi Hisamatsu
No Relationships to Disclose
 
Wataru Ichikawa
Honoraria - Chugai Pharma; Daiichi Sankyo; Merck Serono; Nippon Kayaku; Sawai Pharmaceutical Co; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Daiichi Sankyo; Merck Serono; Ono Pharmaceutical; Zeria Pharmaceutical
Research Funding - Eisai; Taiho Pharmaceutical; Takeda
Travel, Accommodations, Expenses - Daiichi Sankyo
 
Takashi Sekikawa
No Relationships to Disclose
 
Ken Shimada
No Relationships to Disclose
 
Yasutsuna Sasaki
Honoraria - Eisai; Taiho Pharmaceutical; Yakult Pharmaceutical
Research Funding - Boehringer Ingelheim; Chugai Pharma; Eisai; Kyowa Hakko Kirin; Merck Serono; Ono Pharmaceutical; Taiho Pharmaceutical